Actavis Said to Have Rejected $15 Billion Offer From Mylan

Actavis Inc. rejected a cash-and-stock offer from fellow generic-drug maker Mylan Inc. for about $15 billion, deciding instead to pursue talks to take over Warner Chilcott Plc, said people familiar with the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.